Induction Chemo-radiation (50Gy) Followed by Surgery for Stage IIIA-N2 Non-small Cell Lung Cancer.

CONCLUSIONS: Induction chemotherapy with concurrent radiotherapy (50 Gy) followed by surgery was a feasible and promising treatment option for resectable c-stage IIIA-N2 NSCLC. PMID: 29890150 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Ann Thorac Surg Source Type: research

Related Links:

Condition:   Non-small Cell Lung Cancer Interventions:   Biological: pembrolizumab;   Drug: carboplatin;   Drug: paclitaxel;   Drug: pemetrexed Sponsor:   Merck Sharp & Dohme Corp. Active, not recruiting
Source: - Category: Research Source Type: clinical trials
Lung cancer is the leading cause of cancer-related death in the United States with an estimated 234,030 new cases and 154,050 deaths from this disease in 2018 [1]. Of new non-small-cell lung cancer (NSCLC) diagnoses, an estimated 20% or less will be localized to the lung parenchyma without regional or distant metastases; however, this proportion may increase with the adoption of low-dose computed tomography screening for high-risk populations [2]. Standard of care treatment for early stage NSCLC includes lobectomy with mediastinal lymph node sampling; however, many patients may not be suitable candidates for surgical manag...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Conclusion: Our case showed good response to primary tumor and gingival metastasis but not to intestinal obstruction. ALK inhibitor often shows high response rate and long survival for ALK rearrangement NSCLC, however ALK rearranged positive NSCLC with gingival metastasis may have poor prognosis.Case Rep Oncol 2019;12:171 –177
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
Authors: Lantuejoul S, Damotte D, Hofman V, Adam J Abstract Lung cancer is the leading cause of cancer death worldwide with low response rates to conventional chemotherapy. New promising therapies have emerged based on programmed cell death protein 1 (PD-1) immunity checkpoint inhibitors (ICI), including anti-PD-1, such as nivolumab and pembrolizumab, or programmed death ligand 1 (PD-L1) inhibitors, such as atezolizumab, durvalumab, and avelumab. The prescription of pembrolizumab has been approved by FDA and EMA for advanced stages non-small cell lung carcinoma (NSCLC), restricted for first-line setting to patients...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
A biotechnology company specializing in innovative cancer therapeutics has opened a clinical trial examining an immunotherapy drug targeting a protein found in 90 percent of malignant mesothelioma tumors. It is the first clinical trial to specifically study a patient population characterized by this protein expression. The target is known as VISTA, a surface protein which inhibits the immune system from working properly and allows the mesothelioma to grow. The drug is CA-170, an orally available molecule and the only anti-VISTA drug being studied today in a cancer clinical trial. And the potential could be huge. “The...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
In recent years, multiple actionable oncogenic drivers and corresponding targeted agents have been identified in non-small-cell lung cancer (NSCLC) patients. In patients with activating epidermal growth factor receptor (EGFR) mutations improved outcomes with respect to response rate (ORR), progression-free survival (PFS), and quality of life were demonstrated with first- or second-generation EGFR tyrosine kinase inhibitors (TKIs) in comparison to standard first line platinum-based chemotherapy [1 –6].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Opinion statementThe treatment of advanced non-small cell lung cancer (NSCLC) has evolved to include targeted therapy, immunotherapy as well as chemotherapy for selected patients in the first-line setting. Angiogenesis inhibitors have been used in combination with chemotherapy in the first-line and maintenance settings providing improved progression-free survival (PFS) and objective response rate (ORR), as well as overall survival (OS) in selected studies. Biologic rationale exists for combining anti-angiogenic agents with immunotherapy and targeted kinase inhibitors (TKIs). A recent study has demonstrated improved surviva...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
Our study shows that retinoblastoma (RB1) mutation is associated with decreased overall survival in patients with locally advanced and advanced non small cell lung cancer. We also show thatRB1 mutation correlates with lack of response to immunotherapy. AbstractThe retinoblastoma gene (RB1) encodes the retinoblastoma (RB) pocket protein that plays an important role in cell cycle progression. Here we determine the frequency and prognostic significance ofRB1 mutation in non small cell lung cancer (NSCLC), restricting inclusion to Stage III and IV patients with linked genomic and clinical data. The primary outcome was median o...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Pemetrexed;   Drug: Nab-paclitaxel;   Drug: Gemcitabine;   Drug: Docetaxel;   Drug: M7824 Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Abstract OBJECTIVEConcurrent use of anti-PD-1 therapies with stereotactic radiosurgery (SRS) have been shown to be beneficial for survival and local lesional control in melanoma patients with brain metastases. It is not known, however, if immunotherapy (IT) confers the same outcome advantage in lung cancer patients with brain metastases treated with SRS.METHODSThe authors retrospectively reviewed 85 non-small cell lung cancer (NSCLC) patients with brain metastases who were treated with SRS between January 2006 and December 2016. Thirty-nine PD-L1 antibody-positive patients received anti-PD-1 therapy with SRS (IT g...
Source: Journal of Neurosurgery - Category: Neurosurgery Authors: Tags: J Neurosurg Source Type: research
More News: Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study